COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN

被引：2
|
作者：
Castro de Carpeno, J. [1 ]
Castro-Gomez, A. J. [2 ]
Walzer, S. [3 ]
Ray, J. [3 ]
机构：
[1] La Paz Univ Hosp, Madrid, Spain
[2] Roche Farma, Madrid, Spain
[3] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71939-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A259 / A259
页数：1
相关论文
共 50 条
  • [1] A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
    Nuijten, Mark J. C.
    de Castro Carpeno, Javier
    Chouaid, Christos
    Vergnenegre, Alain
    Grossi, Francesco
    Bischoff, Helge
    Heigener, David
    Walzer, Stefan
    [J]. LUNG CANCER, 2012, 76 (03) : 465 - 471
  • [2] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [3] Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
    Greenhalgh, J.
    McLeod, C.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    Dundar, Y.
    Oyee, J.
    Dickson, R.
    Davis, H.
    Green, J.
    McKenna, E.
    Pearson, M.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 33 - 39
  • [4] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [5] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [6] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [7] Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
    Fragoulakis, V. F.
    Pallis, A. G.
    Kaitelidou, D. K.
    Maniadakis, N. M.
    Georgoulias, V. G.
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 43 - 51
  • [8] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    [J]. LUNG CANCER, 2014, 83 : S13 - S13
  • [9] Docetaxel in combination carboplatin as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer
    Barata, F
    Camacho, E
    Sousa, A
    Costa, MS
    Resende, R
    Meleiro, A
    Nogueira, F
    Pereira, A
    Canário, D
    [J]. LUNG CANCER, 2005, 49 : S235 - S235
  • [10] Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
    Douglas, R.
    Campbell, L.
    McAleese, J.
    Scullin, P.
    [J]. LUNG CANCER, 2013, 79 : S9 - S9
12345